CABA vs CAR: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

CAR is the larger of the two ($4.43B market cap): the incumbent the market prices for continued execution (31.17x forward earnings, beta 2.03). CABA is the smaller challenger ($317.11M), priced similarly on forward earnings (-1.36x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

CABA vs CAR: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricCABACARWhat it tells you
Market cap$317.11M$4.43BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E-1.3631.17Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta3.542.03Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range10% of range5% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.

Before you buy: how CABA and CAR affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CABA and CAR share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CABA and CAR exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Cabaletta Bio (CABA) do?

Cabaletta Bio, Inc. (NASDAQ: CABA) is a clinical-stage biotechnology company focused on engineered T cell therapies for autoimmune disease. Its CABA (Cabaletta Approach to B cell Ablation) platform pursues the Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) approach, which uses CD19-directed CAR-T cells to deplete the B cells that drive autoimmune conditions, with the goal of a temporary but complete "immune system reset" rather than chronic suppression. The lead candidate, rese-cel (resecabtagene autoleucel, formerly CABA-201), is a fully human CD19-CAR T cell therapy.

Full CABA guide

What does Avis Budget Group (CAR) do?

Avis Budget Group runs one of the three big global vehicle-rental platforms, operating the Avis, Budget, Budget Truck, Payless and Zipcar brands across airport, off-airport, urban and international markets. Revenue comes from renting a large owned-and-leased vehicle fleet, and the economics hinge on utilization, per-day pricing and the residual value of cars when they are sold out of the fleet. The company competes with privately held Enterprise Holdings, Hertz, Europe's Sixt, and peer-to-peer platforms like Turo and Getaround.

Full CAR guide

CABA vs CAR: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • CABA drivers: Platform aimed at a large autoimmune market; Multi-indication RESET program.
  • CAR drivers: Fleet utilization and pricing recovery; Vehicle residual values and fleet mix.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: CABA is a speculative, pre-revenue clinical-stage stock whose value depends on trial readouts that could fail, slip, or underwhelm. For CAR, the equity is small relative to enormous fleet and corporate debt, so modest swings in used-car residual values, interest rates or demand can move the stock sharply, and the shares carry a beta well above the market.

CABA or CAR: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CABA if you believe its drivers more; CAR if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CABA and CAR guides.

CABA vs CAR: the full fundamentals

CABA. Cabaletta is pre-revenue, so price-to-earnings does not apply; it trades at about 1.2 times book value. With roughly $225 million of cash at the end of June plus about $115 million of warrant proceeds received since, the ~$248 million market value implies the market is assigning little or no value to the rese-cel pipeline itself. Management has noted going-concern considerations, and third-quarter results, expected around November 16, 2026 with consensus at a loss of $0.31 per share, should update cash and runway.

CAR. CAR still does not screen on a trailing price-to-earnings basis because trailing EPS is negative (about -$18), so investors lean on forward earnings (about 21x) and enterprise-value-to-EBITDA (about 21x on trailing EBITDA of roughly $1.54 billion, an EV dominated by fleet debt). At about 0.33x sales and with negative book equity, the stock behaves like a leveraged call on the rental cycle. Figures are approximate and drawn from the company's disclosures through the second quarter of 2026 and consensus estimates as of October 16, 2026.

Headline figures (approximate, October 2026): CABA shows share price ~$1.46 (October 16, 2026), the bottom of a ~$1.46-$4.23 52-week range, market capitalization ~$248 million, cash and debt ~$225 million cash at June 30, 2026, against ~$26 million debt, warrant proceeds ~$115 million received July 1 to September 12, 2026 (~$128 million total from June 2025 warrants); CAR shows revenue (ttm) ~$11.7B, revenue (q2 2026) ~$3.0B, down ~1.3% YoY, q2 2026 eps (actual vs est.) $0.98 vs ~$1.85, net loss (ttm) ~$636M.

The bottom line: CABA vs CAR

CABA and CAR are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CABA and CAR exposure against your real portfolio. It is not an investment adviser.

Wondering how CABA or CAR fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Cabaletta Bio

Ask Walnut's AI anything about CABA and see how it fits what you own.

FAQ

What is the difference between CABA and CAR?

+

Cabaletta Bio, Inc. Avis Budget Group runs one of the three big global vehicle-rental platforms, operating the Avis, Budget, Budget Truck, Payless and Zipcar brands across airport, off-airport, urban and international markets. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is CABA or CAR the better stock?

+

Neither is universally better. CAR is the larger incumbent; CABA is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, CABA or CAR?

+

On forward P/E (as of November 2026), CABA trades at -1.36x and CAR at 31.17x, so CABA is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both CABA and CAR?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of CABA vs CAR?

+

CABA: CABA is a speculative, pre-revenue clinical-stage stock whose value depends on trial readouts that could fail, slip, or underwhelm. The company has reported a going-concern consideration and relies on repeated equity raises and warrant exercises that dilute shareholders; tens of millions of new shares were issued in 2026 alone. Operating cash burn is running at roughly $154 million a year and the trailing net loss is about $181 million. It also competes in a crowded autoimmune cell-therapy field where rivals such as Kyverna are further along toward a first approval, which could affect positioning even if rese-cel succeeds. The stock fell about 43% in the month to October 16, 2026 to a 52-week low near $1.46, which shows how quickly sentiment can turn, and a single negative data point or financing setback can move it sharply again. CAR: The equity is small relative to enormous fleet and corporate debt, so modest swings in used-car residual values, interest rates or demand can move the stock sharply, and the shares carry a beta well above the market. Negative stockholders' equity leaves little cushion if losses continue, and refinancing large maturities is an ongoing requirement rather than a one-time event. Competition from Enterprise, Hertz, Sixt and peer-to-peer platforms limits pricing power, and further EV or fleet writedowns remain possible. Results are also seasonal, with the first quarter typically the weakest, which can exaggerate headline losses. Execution against estimates has been uneven in 2026: Q1 EPS of -$8.01 came in below the -$7.50 consensus and Q2 EPS of $0.98 roughly halved expectations, and the shares fell about 32 percent over the three months to October 16, 2026. Revenue was down about 1.3 percent year over year in Q2, so the earnings recovery depends on cost and fleet discipline more than demand growth.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell CABA or CAR; figures are approximate and dated (as of November 2026). Verify current data before investing.